Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4574448
Max Phase: Preclinical
Molecular Formula: C42H41N7Na2O10S2
Molecular Weight: 869.98
Molecule Type: Unknown
Associated Items:
ID: ALA4574448
Max Phase: Preclinical
Molecular Formula: C42H41N7Na2O10S2
Molecular Weight: 869.98
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=c1c2ccccc2nc(-c2ccc(OS(=O)(=O)[O-])cc2)n1CCCCCCCCCCCn1cc(Cn2c(-c3ccc(OS(=O)(=O)[O-])cc3)nc3ccccc3c2=O)nn1.[Na+].[Na+]
Standard InChI: InChI=1S/C42H43N7O10S2.2Na/c50-41-35-14-8-10-16-37(35)43-39(30-18-22-33(23-19-30)58-60(52,53)54)48(41)27-13-7-5-3-1-2-4-6-12-26-47-28-32(45-46-47)29-49-40(44-38-17-11-9-15-36(38)42(49)51)31-20-24-34(25-21-31)59-61(55,56)57;;/h8-11,14-25,28H,1-7,12-13,26-27,29H2,(H,52,53,54)(H,55,56,57);;/q;2*+1/p-2
Standard InChI Key: DNSGIUFCRVHSIB-UHFFFAOYSA-L
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 869.98 | Molecular Weight (Monoisotopic): 869.2513 | AlogP: 6.65 | #Rotatable Bonds: 20 |
Polar Surface Area: 227.69 | Molecular Species: ACID | HBA: 15 | HBD: 2 |
#RO5 Violations: 3 | HBA (Lipinski): 17 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: -2.84 | CX Basic pKa: 4.69 | CX LogP: 8.24 | CX LogD: 3.13 |
Aromatic Rings: 7 | Heavy Atoms: 61 | QED Weighted: 0.06 | Np Likeness Score: -0.64 |
1. Morla S, Sankaranarayanan NV, Afosah DK, Kumar M, Kummarapurugu AB, Voynow JA, Desai UR.. (2019) On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients., 62 (11): [PMID:31074986] [10.1021/acs.jmedchem.9b00379] |
2. Boothello RS, Sankaranarayanan NV, Afosah DK, Karuturi R, Al-Horani RA, Desai UR.. (2020) Studies on fragment-based design of allosteric inhibitors of human factor XIa., 28 (23.0): [PMID:32992249] [10.1016/j.bmc.2020.115762] |
Source(1):